# Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

Source: https://onco.cc/trials/nct05491226/  
OnCo record `nct05491226` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pembrolizumab in triple-negative breast cancer, run by Stephen Shiao, now recruiting.

## Summary

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation is a phase 2, interventional study registered as NCT05491226 by Stephen Shiao, with a registry enrolment figure of 35 participants, started 2023-11-17 and due to reach its primary completion in 2026-12-01. Interventions recorded: Pembrolizumab; Radiation Therapy; Axatilimab. Conditions listed: TNBC - Triple-Negative Breast Cancer; Breast Cancer. Triple-negative eligibility wording from the registry: "* Female patients diagnosed with high-risk triple negative breast cancer (TNBC) with intent for neoadjuvant therapy". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05491226
- Phase: 2
- Setting: IIT2021-01-Shiao-CSF1Ri: Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
- Sponsor: Stephen Shiao
- Enrolled: 35

## Sources

- ClinicalTrials.gov NCT05491226: https://clinicaltrials.gov/study/NCT05491226

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05491226.json